Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intra-Cellular Therapies Inc ITCI

Healthcare
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical... see more

Recent & Breaking News (NDAQ:ITCI)

Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2021

Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast

GlobeNewswire August 2, 2021

CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology

GlobeNewswire June 7, 2021

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

GlobeNewswire May 26, 2021

Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 10, 2021

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

GlobeNewswire May 5, 2021

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

GlobeNewswire May 3, 2021

Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting

GlobeNewswire April 22, 2021

Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting

GlobeNewswire April 20, 2021

Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire April 12, 2021

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update

GlobeNewswire February 25, 2021

Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284

GlobeNewswire February 24, 2021

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression

GlobeNewswire February 22, 2021

Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference

GlobeNewswire February 19, 2021

Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast

GlobeNewswire February 17, 2021

CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research

GlobeNewswire January 21, 2021

Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2021

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

GlobeNewswire December 29, 2020

Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology

GlobeNewswire December 9, 2020

Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference

GlobeNewswire November 30, 2020